https://www.selleckchem.com/pr....oducts/vazegepant-hy
Invasion depth, differentiation, and tumor size differed significantly in high-risk patients. Overall 3-year survival rates were 94.2% (low-risk) and 40.9% (high-risk) (p less then 0.01). Twenty-one patients with sm1 cancer, high tumor differentiation, and tumor length less then 2 cm had no lymph node metastasis or lymphovascular invasion, and none of these patients experienced recurrence. CONCLUSIONS Endoscopic submucosal resection alone may be feasible for patients with small (≤ 2 cm) clinically N0 submucosal esoph
Like
Comment
Share
